Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hangzhou Ruipu Chenchuang Technology

Request full access

A regenerative medicine company leveraging stem cell therapy to address diabetes, with plans to expand its application to other disease areas

Hangzhou, ChinaFounded 2014Biotech & Life Sciences

About Hangzhou Ruipu Chenchuang Technology

Hangzhou Ruipu Chenchuang Technology, operating as ReproGenix Bioscience, is a regenerative medicine company established in 2014, with a strategic focus on developing stem cell-based therapies. The company was co-founded by Professor Hongkui Deng, a distinguished stem cell researcher and Director of the Peking University Stem Cell Research Center; Dr. Lieming Ding, a seasoned pharmaceutical industry leader; and Casey Lou, a serial entrepreneur who serves as CEO. Professor Deng's pioneering work in non-genetic cellular reprogramming technologies provides the scientific foundation for the company's core technology.

ReproGenix is centered on the clinical application of chemically induced pluripotent stem cells (CiPSCs) to address significant unmet medical needs, primarily diabetes. The company's business model involves intensive research and development to bring proprietary cell therapies through clinical trials to commercialization. Its operations encompass a comprehensive platform that integrates research, manufacturing under GMP conditions, and clinical translation. The company's lead product is RGB-5088, an islet cell injection derived from CiPSCs designed for diabetes therapy. This product represents a potential paradigm shift, moving from disease management to a curative-intent therapy.

A landmark achievement for the company was the successful treatment of a type 1 diabetes patient, who became insulin-independent within 75 days of receiving the RGB-5088 transplant, a result that was replicated in subsequent patients. This breakthrough, published in the journal *Cell*, demonstrated the safety and efficacy of the therapy in a pilot clinical study. Following these results, RGB-5088 received Investigational New Drug (IND) approval in China, and a Phase 1 clinical trial has commenced. ReproGenix anticipates starting Phase 2/3 trials in 2026, with a target for a Biologics License Application (BLA) filing in China by 2027. To support its clinical pipeline and bioprocess optimization, the company plans to raise significant capital.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
20.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, Cell Therapy, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Nov 2025 $69M $344M Betta Pharmaceuticals · Yuansheng BioVenture · Chinese Reform Holdings Corporation · Gage Finance ↗
SERIES AOther financing Nov 2024 $14M $55M Lenovo Capital and Incubator Group (LCIG) · Hetang Venture Capital Management (Beijing) · China Ventures Fund · Beda Pharmaceuticals ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Hangzhou Ruipu Chenchuang Technology website traffic

Latest recorded traffic for Hangzhou Ruipu Chenchuang Technology is 180 monthly website visits, up 0% over the last three months.

Latest monthly visits180 3-month web change0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hangzhou Ruipu Chenchuang Technology in the Hangzhou ecosystem

Live from Dealroom

The Hangzhou Ruipu Chenchuang Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A12 investors entered at this stage

  • China Ventures Fund
  • Lenovo Capital and Incubator Group (LCIG)
  • Hetang Venture Capital Management (Beijing)
  • Beda Pharmaceuticals
  • Betta Pharmaceuticals
  • Yuansheng BioVenture
  • Chinese Reform Holdings Corporation
  • Gage Finance
  • Sinowisdom
  • Yuhang Guotou
  • Hangzhou Oriental Jiafu Asset Management
  • ZSCO

Other known investors1 additional known investor

  • Peking University
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Hangzhou HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hangzhou Ruipu Chenchuang Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hangzhou Ruipu Chenchuang Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.